Latigo Biotherapeutics, Inc.: 5%+ holders

As of November 7, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Latigo Biotherapeutics, Inc. The largest reported stake is Dr. Beth C. Seidenberg's, at 19.9%. 6 filings are on record since August 13, 2026 (Schedule 13G, October 29, 2026).

Westlake BioPartners Fund I, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Latigo Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-06 · Reporting person: AI Biotechnology LLC · Sole voting: 0 · Shared voting: 3,193,565 · Sole dispositive: 0 · Shared dispositive: 3,193,565 · SCHEDULE 13G/A, 2026-11-06
• Filing 2026-10-29 · Reporting person: Westlake BioPartners Fund I, L.P. · Sole voting: 5,944,009 · Shared voting: 5,944,009 · Sole dispositive: 5,944,009 · Shared dispositive: 5,944,009 · SCHEDULE 13G, 2026-10-29
• Filed 2026-08-18 · Holder: AI Biotechnology LLC · Percent: 5% · SCHEDULE 13G
• Filing 2026-08-17 · Reporting person: Foresite Capital Fund VI LP · Sole voting: 2,203,800 · Shared voting: 0 · Sole dispositive: 2,203,800 · Shared dispositive: 0 · SCHEDULE 13D, 2026-08-17
• Filing 2026-08-17 · Reporting person: RA Capital Management, L.P. · Sole voting: 0 · Shared voting: 5,295,690 · Sole dispositive: 0 · Shared dispositive: 5,295,690 · SCHEDULE 13G, 2026-08-17

Latigo Biotherapeutics, Inc. has 6 Schedule 13D or 13G filings on record since 2026-08-13. 4 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Latigo Biotherapeutics, Inc. and the warning signs.

See Latigo Biotherapeutics, Inc.'s free Snapshot Watch Latigo Biotherapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Latigo Biotherapeutics, Inc. and the records around it.

Latigo Biotherapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• Westlake BioPartners Fund I, L.P. also filed stake reports on 2 other companies: Electra Therapeutics, Inc. (Oct 2026), Kyverna Therapeutics, Inc. (Feb 2026)
• AI Biotechnology LLC also filed stake reports on 3 other companies: Yarrow Bioscience, Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026), Zura Bio Limited (Mar 2026)
• Foresite Capital Fund VI LP also filed stake reports on 4 other companies: IRulya Therapeutics Inc. (Oct 2026), Alumis Inc. (Aug 2026), Verastem, Inc. (May 2026)

Want the whole picture on Latigo Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Latigo Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Latigo Biotherapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Latigo Biotherapeutics, Inc. by CUSIP 517954103 and gives its principal executive office as 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oaks, CA 91320 (SCHEDULE 13G/A, 2026-11-06).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.RA Capital Management, L.P., SCHEDULE 13G, 2026-08-17

See the responses to Item 11 on the attached cover pages. The percentages reported in Item 11 on the attached cover pages are based upon 66,299,347 shares of Common Stock outstanding as of November 2, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on November 5, 2026.AI Biotechnology LLC, SCHEDULE 13G/A, 2026-11-06

Source of funds (Item 3)

Direct Purchase of Series A-2 Convertible Preferred Stock In September 2022, Fund V purchased an aggregate of 10,014,576 shares of Series A-2 Convertible Preferred Stock of the Issuer, Opportunity Fund V purchased an aggregate of 10,014,576 shares of Series A-2 Convertible Preferred Stock of the Issuer and Fund VI purchased an aggregate of 2,225,461 shares of Series A-2 Convertible Preferred Stock of the Issuer at a price of $0.89869 per share, or $20,000,009.70 in the aggregate.Foresite Capital Fund VI LP, SCHEDULE 13D, 2026-08-17

Purpose of Transaction (Item 4)

Foresite Capital Fund VI LP

The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock; general market and economic conditions; ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities; and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D filed 2026-08-17

Timeline

Swipe the table sideways to see every column.

Questions about who owns Latigo Biotherapeutics, Inc.

Who owns Latigo Biotherapeutics, Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of Latigo Biotherapeutics, Inc.: Dr. Beth C. Seidenberg (19.9%, Schedule 13G, filed 2026-10-29), Foresite Capital Fund VI LP (14.5%, Schedule 13D, filed 2026-08-17), RA Capital Management, L.P. (8.4%, Schedule 13G, filed 2026-08-17) and Deep Track Capital, LP (7.03%, Schedule 13G, filed 2026-08-13).

Who are the largest shareholders of Latigo Biotherapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Latigo Biotherapeutics, Inc. on this page are Dr. Beth C. Seidenberg (19.9%), Foresite Capital Fund VI LP (14.5%) and RA Capital Management, L.P. (8.4%).

When did Dr. Beth C. Seidenberg buy into Latigo Biotherapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Dr. Beth C. Seidenberg on this page is the Schedule 13G, filed 2026-10-29, reporting 19.9%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Latigo Biotherapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Latigo Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Latigo Biotherapeutics, Inc. is mentioned again
• Find former Latigo Biotherapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes